Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (Otsuka)

Protocol Name: Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)

Sponsor: Otsuka

Indication: IgA Nephropathy

Primary Investigator: Dr. Bernard Fischbach

Location:Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246

DETAILS >